Trusted reliable news sources from around the web. We offer special news reports, topic news videos, and related content stories. Truly a birds eye view on news.
Dubai, UAE, March 29, 2026 (GLOBE NEWSWIRE) -- Pepeto is approaching the Binance listing, and the intensity building around this project mirrors what surrounded Dogecoin before it created millionaires. Rounds close within days as the bitcoin price holds at $66,496 amid extreme market fear, and crypto news data shows the wallets entering share the same…
Washington, D.C., March 29, 2026 (GLOBE NEWSWIRE) -- The numbers behind the artificial intelligence buildout are staggering. Billions of dollars committed to data centers. Advanced chip acquisitions are accelerating. Cloud infrastructure expanding at a pace few could have anticipated even two years ago. To most observers, it reads as a story of progress. To Jim…
Bitcoin Everlight opens Phase 3 presale as stablecoin adoption draws broader retail attention to digital asset participation SAN FRANCISCO, March 29, 2026 (GLOBE NEWSWIRE) -- Bitcoin Everlight, a transaction routing and validation network operating alongside the Bitcoin blockchain, has opened Phase 3 of its public presale with BTCL priced at $0.0012 per token. The launch…
NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Alight, Inc. (NYSE: ALIT) and certain of its officers.
NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). A class action lawsuit…
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney…
RSS
